ABG Sundal Collier acts as Joint Lead Manager and Joint Bookrunner in the proposed NOK 360 million rights issue in PCI Biotech Holding ASA

On Friday 24 August, PCI Biotech Holding ASA announced the intention to carry out a fully underwritten
rights issue of NOK 360 million. The rights issue is fully underwritten by an underwriting syndicate
established by the Joint Bookrunners, including the Company’s largest shareholders and the international
specialist investor Nyenburgh, as well as other institutional investors.
The net proceeds from the rights issue will finance the company’s clinical development programme well into
2022, beyond the anticipated interim read-out of the planned pivotal fimaCHEM study in 2021 and potential
regulatory submission for accelerated/conditional marketing authorisation in 2022 as well as certain other
activities related to the fimaCHEM study.
About PCI Biotech Holding ASA
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel
therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology
platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of
chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic
vaccination), and fimaNAc (nucleic acid therapeutics delivery). For more information, please visit
www.pcibiotech.no